Read the full article here.
This content was originally published by MarketWatch.com - Top Stories. Original publishers retain all rights. It appears here for a limited time before automated archiving. By MarketWatch.com - Top Stories
Gilead Sciences Inc. is nearing a deal to buy biotech Immunomedics Inc. and its prized breast-cancer drug for more than $20 billion.